The aim of this thesis is to evaluate outcome prediction and clinical relevance of the 70-gene signature for locoregional and distant recurrence, its influence on risk assessment and adjuvant systemic therapy (AST) recommendations, and its additional value to established clinical guidelines used in breast cancer treatment. In addition, we used the 70-gene signature to gain better insight in the biological background of tumors detected in a population-based screening program
The invention provides for malignancy-risk gene signatures that predict the risk of developing breas...
BACKGROUND: A 70-gene signature was previously shown to have prognostic value in patients with node-...
AbstractGene signatures have been developed for estrogen receptor-positive breast cancer to compleme...
Clinical guidelines for breast cancer treatment differ in their selection of patients at a high risk...
BACKGROUND: The 70-gene signature test (MammaPrint) has been shown to improve prediction of clinical...
Background The 70-gene signature test (MammaPrint) has been shown to improve prediction of clinical ...
BACKGROUND: The 70-gene signature test (MammaPrint) has been shown to improve prediction of clinical...
Gene expression classifiers such as the 70-gene signature that reflect the biology of breast tumours...
OBJECTIVE: The 70-gene signature test (MammaPrint) has been shown to improve prediction of clinical ...
Background. A 70-gene signature was previously shown to have prognostic value in patients with node-...
The 70-gene signature (MammaPrint™) has been developed on retrospective series of breast cancer pati...
The 70-gene signature (MammaPrint (TM)) has been developed to predict the risk of distant metastases...
Background: Strategies for breast cancer care are improving. However, there is a clinical need for a...
The 70-gene signature (MammaPrint) is a prognostic tool used to guide adjuvant treatment decisions. ...
Cancer is a complex disease which arises due to a series of genetic changes related to cell division...
The invention provides for malignancy-risk gene signatures that predict the risk of developing breas...
BACKGROUND: A 70-gene signature was previously shown to have prognostic value in patients with node-...
AbstractGene signatures have been developed for estrogen receptor-positive breast cancer to compleme...
Clinical guidelines for breast cancer treatment differ in their selection of patients at a high risk...
BACKGROUND: The 70-gene signature test (MammaPrint) has been shown to improve prediction of clinical...
Background The 70-gene signature test (MammaPrint) has been shown to improve prediction of clinical ...
BACKGROUND: The 70-gene signature test (MammaPrint) has been shown to improve prediction of clinical...
Gene expression classifiers such as the 70-gene signature that reflect the biology of breast tumours...
OBJECTIVE: The 70-gene signature test (MammaPrint) has been shown to improve prediction of clinical ...
Background. A 70-gene signature was previously shown to have prognostic value in patients with node-...
The 70-gene signature (MammaPrint™) has been developed on retrospective series of breast cancer pati...
The 70-gene signature (MammaPrint (TM)) has been developed to predict the risk of distant metastases...
Background: Strategies for breast cancer care are improving. However, there is a clinical need for a...
The 70-gene signature (MammaPrint) is a prognostic tool used to guide adjuvant treatment decisions. ...
Cancer is a complex disease which arises due to a series of genetic changes related to cell division...
The invention provides for malignancy-risk gene signatures that predict the risk of developing breas...
BACKGROUND: A 70-gene signature was previously shown to have prognostic value in patients with node-...
AbstractGene signatures have been developed for estrogen receptor-positive breast cancer to compleme...